WO2000073463A1 - Groel muteins with improved stability - Google Patents
Groel muteins with improved stability Download PDFInfo
- Publication number
- WO2000073463A1 WO2000073463A1 PCT/GB2000/002019 GB0002019W WO0073463A1 WO 2000073463 A1 WO2000073463 A1 WO 2000073463A1 GB 0002019 W GB0002019 W GB 0002019W WO 0073463 A1 WO0073463 A1 WO 0073463A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polypeptide
- protein
- chaperone
- groel
- molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to chaperone polypeptides having improved stability which are active in the folding and maintenance of structural integrity of other proteins.
- Chaperones are in general known to be large multisubunit protein assemblies essential in mediating polypeptide chain folding in a variety of cellular compartments.
- Several families of chaperones have been identified, for example the chaperonin hsp60 family, otherwise known as the cpn60 class of proteins, which are expressed constitutively.
- Members of the chaperonin hsp60 family have been identified in the bacterial cytoplasm (GroEL), in endosymbiotically derived mitochondria (hsp60) and in chloroplasts (Rubisco binding protein).
- Another chaperone family, designated TF55/TCP1 is found in the thermophilic archaea and the evolutionarily connected eukaryotic cytosol.
- a comparison of amino acid sequence data has shown that there is at least 50% sequence identity between chaperones found in prokaryotes. mitochondria and chloroplasts.
- the molecular chaperone GroEL assists the folding of many newly synthesized proteins in Escherichia coli (E. coli) (Gething & Sambrook. 1992).
- the active site of GroEL which is responsible for the binding of polypeptide substrates, is located on two helices H8 and H9 as well as an adjacent loop (residues 199 to 204) of the apical domain (residues 191 to 376) (Fenton et al. , 1994; Buckle et al, 1997).
- Polypeptides corresponding to the apical domain of GroEL and fragments thereof, termed minichaperones, are active in vitro, facilitating the refolding of rhodanese and cyclophilin A (CyPA) and catalysing the unfolding of native barnase (Zahn et al, 1996), and in vivo complementing temperature sensitive mutants of GroEL (Chatellier et al., 1998).
- the essential chaperone activity does not require the allosteric properties and central cavity provided by intact GroEL, which are refinements for optimal activity (Ben-Zvi et al, 1998).
- protein refolding in vitro often takes place over a range of conditions that are not suited to the use of wild type minichaperone polypeptides, such as high urea or guanidium chloride concentrations or high temperatures, since the wild type minichaperone polypeptides are not stable under such conditions.
- protein stability is not generally optimized during evolution.
- the stability of the minichaperone GroEL(193- 345) is relatively low (L G»J of 6.6 kcal mob 1 ).
- minichaperone polypeptides having enhanced stability.
- a more stable minichaperone could be used over a wide range of more stringent conditions, such as high denaturant concentration or high temperature.
- an enhancement in protein stability may be achieved in theory by designed amino acid substitutions, a rational approach to stabilization is extremely difficult since it is not generally possible to predict the energetic and structural response to mutation.
- the statistics of isolated helices and parts of sheets are predictable to various extents (Regan et al. 1996). but effects in proteins are often strongly dependent on the structural context.
- the present invention provides a GroEL chaperone polypeptide. or homologue thereof, or fragment thereof having protein refolding activity, comprising one or more amino acid modifications at any one of amino acid residues 207, 212, 217. 223, 233, 267, 271. 294. 305, 308 and 326 of the GroEL amino acid sequence shown as SEQ I.D. No. 1 or their equivalent positions in other homologous chaperone polypeptides.
- the modifications are amino acid substitutions.
- said substitutions are selected from Lys207 ⁇ Asn. Ala212 ⁇ Glu, Ser217 ⁇ Asp, Ala223 ⁇ Thr, Ala223 ⁇ Val. Met233 ⁇ Leu, Met267 ⁇ Leu. Val271 ⁇ Leu. Val271 ⁇ Ser, Thr294 ⁇ Arg, Ile305 ⁇ Leu and Glu308— »Lys. Asn326— Thr, and their equivalents in other homologous chaperone polypeptides.
- the polypeptide of the invention comprises a combination of at least two amino acid modifications.
- a particularly preferred combination is [Ala212-->Glu, Ala223 ⁇ Thr, Met233 ⁇ Leu, Ile305 ⁇ Leu, Glu308 ⁇ Lys and Asn326 ⁇ Thr] or [Ala212 ⁇ Glu, Ala223 ⁇ Val, Met233 ⁇ Leu, Ile305 ⁇ Leu, Glu308 ⁇ Lys and Asn326— Thr], or their equivalents in other homologous chaperone polypeptides.
- the polypeptide of the invention consists essentially of amino acids 193 to 335, 191 to 337, 191 to 345 or 191 to 376 of GroEL or the equivalent residues of homologous chaperone polypeptides.
- the polypeptide of the invention when in solution, remains monomeric and has the ability to refold, reactivate or recondition proteins.
- the present invention also provides a nucleic acid molecule encoding a polypeptide of the invention. Also provided is a vector comprising a nucleic acid of the invention, optionally operably linked to a regulatory sequence capable of directing expression of said nucleic acid in a suitable host cell. A host cell comprising a nucleic acid or a vector of the invention is also provided.
- the present invention provides a method of making a polypeptide of the invention comprising transforming a host cell with a nucleic acid encoding said polypeptide, culturing the transformed cell and expressing said polypeptide.
- the present invention further provides a pharmaceutical composition
- a pharmaceutical composition comprising a polypeptide of the invention or a nucleic acid of the invcNon together with a pharmaceutically acceptable diluent, carrier or excipient.
- the present invention provides a polypeptide. nucleic acid, vector or pharmaceutical composition of the invention for use in therapy. Also provided is the use of a polypeptide, nucleic acid, vector or pharmaceutical composition of the invention for use in the manufacture of a medicament for the treatment of disease associated with protein/polypeptide structure.
- the present invention also provides a method of reconditioning a molecule comprising contacting said molecule with the chaperone polypeptide of the invention.
- the molecule is a protein/polypeptide.
- the molecule is subjected to inactivation or denaturation prior to contacting with said chaperone polypeptide.
- the chaperone polypeptide is immobilised to a solid phase. More preferably the solid phase is a chromatographic matrix and the contacting of the molecule and chaperone polypeptide is carried out by applying the molecule to the top of a bed of the matrix packed in a column and then eluting the molecule through the column.
- the present invention further provides the use of a polypeptide of the invention for altering the structure of a molecule.
- the molecule is a protein or polypeptide and the alteration in structure is by folding, unfolding or refolding.
- the stoichiometry between the chaperone polypeptide and the molecule being altered is about 1 : 1.
- the present invention also provides the use of a polypeptide of the invention for purifying or increasing the yield, specific activity or quality of biological molecules.
- kits for reconditioning or refolding a molecule comprising a polypeptide according to the invention immobilised to a solid phase and a container for holding said solid phase polypeptide.
- the invention provides the use of a chaperone polypeptide of the invention in the production of a protein or polypeptide by recombinant means, wherein the said chaperone polypeptide is co-expressed with the protein or polypeptide thereby to improve the yield, specific activity or quality of the protein or polypeptide.
- the invention provides a method of treating a human or animal patient suffering from a disease associated with protein/polypeptide structure which method comprises administering to a patient an effective amount of a polypeptide or polynucleotide of the invention Detailed description of the invention
- GroEL is a member of the hsp ⁇ O family of heat shock proteins.
- GroEL is a tetradecamer wherein each monomeric subunit (cpn ⁇ Om) has a molecular weight of approximately 57 kDa.
- the tetradecamer facilitates the in vitro folding of a number of proteins which would otherwise misfold or aggregate and precipitate.
- the structure of GroEL from E- coli has been established through X-ray crystallographic studies (see Braig K. et al, 1994.
- the holo protein is cylindrical, consisting of two seven-membered rings that form a large central cavity which is generally considered to be essential for activity.
- E. coli Gro ⁇ L The entire amino acid sequence of E. coli Gro ⁇ L is also known (see Braig K et al, 1994) and three domains have been ascribed to each cpn ⁇ Om of the holo chaperonin (tetradecamer). These are the intermediate (amino acid residues 1-5, 134-190, 377-408 and 524-548), equatorial (residues 6-133 and 409-523) and apical (residues 191 -376) domains.
- Gro ⁇ L facilitates the folding of a number of proteins by two mechanisms; (1) it prevents aggregation by binding to partly folded proteins, which then refold on Gro ⁇ L to a nativelike state and (2) it continuously anneals misfolded proteins by unfolding them to a state from which refolding can start again.
- Chaperone activity may be determined in practice by an ability to refold cyclophilin A but other suitable proteins such as glucosamine-6-phosphate deaminase or a mutant form of indoleglycerol phosphate synthase (IGPS) (amino acid residues 49-252) may be used.
- IGPS indoleglycerol phosphate synthase
- a rhodanese refolding assay may also be used. Details of a suitable refolding assay are given below and in the examples.
- Preferred chaperone polypeptides of the present invention have protein refolding activity in the absence of adenosine triphosphate of more than 50%, preferably 60%. even more preferably 75%, ----- J refolding activity being determined by contacting the chaperone polypeptide with an inactivated protein of known specific activity prior to inactivation, and then determining the specific activity of the said protein after contact with the polypeptide.
- the % refolding activity being:
- the chaperone activity is determined by the refolding of cyclophilin A. More preferably. 8 M urea denatured cyclophilin A (100 ⁇ M) is diluted into 100 mM potassium phosphate buffer pH7.0, 10 mM DTT to a final concentration of l ⁇ M and then contacted with at least l ⁇ M of said polypeptide at 25°C for at least 5 min, the resultant cyclophilin A activity being assayed by the method of Fischer et al. (1984).
- chaperone polypeptides of the present invention are monomeric in solution and incapable of multimerisation in solution.
- Monomeric GroEL minichaperones are disclosed in W098/13496.
- multimerisation is prevented by using chaperone polypeptides that lack the interacting domains found outside the apical domain, although it could be achieved by suitable mutations.
- a GroEL chaperone polypeptide, or homologue thereof, of the present invention comprises at least one modified amino acid residue selected from amino acids 207, 212, 217, 223, 233, 267, 271. 294, 305, 308 and 326 of the GroEL amino acid sequence shown as SEQ ID No. 1 or their equivalent positions in other homologous chaperone polypeptides. It is preferred that said modifications are amino acid substitutions. In particular is it preferred that the amino acid substitutions are selected from the following specific substitutions exemplified herein, i.e. Lys207— Asn, Ala212-»Glu, Ser217— ->Asp, Ala223— - Thr, Ala223 ⁇ Val.
- the polypeptide of the invention comprises modifications selected from [Ala212— - Glu, Ala223 ⁇ Thr, Met233 ⁇ Leu, Ile305->Leu. Glu308 ⁇ Lys and Asn326 ⁇ Thr], and [Ala212 ⁇ Glu, Ala223 ⁇ Val, Met233 ⁇ Leu, Ile305 ⁇ Leu, Glu308 ⁇ Lys and Asn326— »Thr], and their equivalents in other homologous chaperone polypeptides.
- polypeptides of the invention will generally comprise at least amino acids 193 to 335 of GroEL. or their equivalents in other chaperone polypeptides.
- Other preferred fragments include amino acids 193 to 335, 191 ie 7, 191 to 345 and 191 to 376 of GroEL or their equivalents in other chaperone polypeptides.
- modified polypeptides of the invention are not limited to GroEL polypeptides based on the amino acid sequence set out in SEQ. ID. No. 1 or fragments thereof having chaperone activity but also include homologous chaperone polypeptides sequences obtained from any source, for example related viral/bacterial proteins, cellular homologues and synthetic peptides, as well as variants or derivatives thereof.
- polypeptides of the invention may also be based on chaperone homologues from other species including bacteria such as E. coli, yeast and animals such as mammals (e.g. mice, rats or rabbits), especially primates, more especially humans.
- the present invention covers variants, homologues or derivatives of the amino acid sequence set out in SEQ ID No. 1 which comprise similar stabilising modifications as those described for GroEL, as well as variants, homologues or derivatives of the nucleotide sequences coding for the amino acid sequences of the present invention.
- modified chaperone polypeptides of the invention have an increased stability, as measured by ⁇ G ⁇ D »» ⁇ --. , of at least - 0.1 kcal mob 1 , preferably at least -0.2, -0.4,
- ⁇ G; «- ⁇ » may be determined as described in the examples.
- a homologous sequence is taken to include an amino acid sequence which is at least 30, 40, 50. 60. 70. 80 or 90% identical, preferably at least 95 or 98% identical at the amino acid level over at least 50 or 100. preferably 200, 300. 400 or 500 amino acids with SEQ ID No. 2.
- homology should typically be considered with respect to those regions of the sequence known to be essential for protein function rather than non-essential neighbouring sequences. For example, homology may be compared with amino acids 191 to 376 (apical domain) of SEQ ID No. 1.
- homology can also be considered in terms of similarity (i.e. amino acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.
- Homology comparisons can be conducted by eye. or more usually, with the aid of readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.
- % homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence directly compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues (for example less than 50 contiguous amino acids). Although this is a very simple and consistent method, it fails to take into consideration that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.
- GCG Bestfit program Although the final % homology can be measured in terms of identity, the alignment process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance.
- An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs.
- GCG Wisconsin programs generally use either the public default values or a custom symbol comparison table if supplied (see user manual for further details). It is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.
- the skilled person can identify suitable homologues by, for example, carrying out a search of online databases using all or part of SEQ ID. No. 1 as a query sequence. For example, a search of the Swissprot database using the BlastP program Ver 2.0.8 (default settings) (Jinghui Zhang et al, 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”. Nucleic Acids Res. 25:3389-3402) and ammo acids 191 to 376 of SEQ ID No. 1 as the query sequence identified well over a hundred homologous sequences, many of which gave homology scores of at least 50% identity.
- Homologues identified include members of the hsp ⁇ O chaperonin family which includes the eubacterial GroEL, mitochondrial hsp ⁇ O and chloroplast cpn60. Other specific homologues together with their database accession numbers are detailed in W098/13496.
- variant or derivative in relation to the amino acid sequences of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the sequence providing the resultant amino acid sequence retains substantially the same activity as the unmodified sequence, preferably having at least the same activity as the wild type polypeptide from which the variant or derivative is derived (such as the GroEL sequence shown in SEQ ID. No. 1).
- a suitable assay for determining activity is described above.
- Polypeptides having the amino acid sequence shown in SEQ I.D. No. 1 , or fragments or homologues thereof may be modified for use in the present invention. Typically, modifications are made that maintain the biological activity of the sequence.
- Amino acid substitutions may be made, for example from 1 , 2 or 3 to 10. 20 or 30 substitutions provided that the modified sequence retains the biological activity of the unmodified sequence.
- Guidance is given herein as to certain modifications that enhance stability of the chaperone polypeptides of the present invention.
- Guidance is also given herein as to modifications that do not impair protein stability as well as modifications that reduce protein stability. Modifications that reduce protein stability should be avoided.
- Amino acid substitutions may include the use of non-naturally occurring analogues, for example to increase blood plasma half-life of a therapeutically administered polypeptide.
- Polypeptides of the invention also include fragments of the full length sequences mentioned above having chaperone activity. Preferably said fragments comprise at least the apical domain of GroEL or its equivalent in chaperone homologues.
- Polypeptides of the invention may further comprise heterologous amino acid sequences, typically at the N-terminus or C-terminus. preferably the N-terminus Heterologous sequence may include sequences that affect intra or extracellular protein targeting (such as leader sequences). Heterologous sequences may also include sequences that increase the immunogenicity of the polypeptide of the invention and/or which facilitate identification, extraction and/or purification of the polypeptides.
- polyamino acid sequence such as polyhistidine which is preferably N-terminal.
- Polypeptides of the invention are typically made by recombinant means, for example as described below. However they may also be made by synthetic means using techniques well known to skilled persons such as solid phase synthesis. Polypeptides of the invention may also be produced as fusion proteins, for example to aid in extraction and purification. Examples of fusion protein partners include glutathione-S-transferase (GST), ⁇ xHis, GAL4 (DNA binding and/or transcriptional activation domains) and ⁇ -galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences, such as a thrombin cleavage site. Preferably the fusion protein will not hinder the function of the protein of interest sequence.
- mammalian homologues may preferably be expressed using mammalian host cells.
- Polypeptides of the invention may be in a substantially isolated form. It will be understood that the protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the protein and still be regarded as substantially isolated.
- a polypeptide of the invention may also be in a substantially purified form, in which case it will generally comprise the protein in a preparation in which more than 90%, e.g. 95%, 98% or 99%) of the protein in the preparation is a polypeptide of the invention.
- a polypeptide of the invention may be labelled with a revealing label.
- the revealing label may be any suitable label which allows the polypeptide to be detected. Suitable labels include radioisotopes, e.g. I23 I, enzymes, antibodies, polvnucleotides and linkers such as biotin.
- a polypeptide or labelled polypeptide of the invention or fragment thereof may also be fixed to a solid phase, for example a chromatographic matrix such as sepharose.
- a chromatographic matrix such as sepharose.
- Such labelled and/or immobilised polypeptides may be packaged into kits in a suitable container along with suitable reagents, controls, instructions and the like.
- Polvnucleotides of the invention comprise polvnucleotides encoding the polypeptides of the invention. It will be understood by a skilled person that numerous different polvnucleotides can encode the same polypeptide as a result of the degeneracy of the genetic code. In addition, it is to be understood that skilled persons may. using routine techniques, make nucleotide substimtions that do not affect the polypeptide sequence encoded by the polvnucleotides of the invention to reflect the codon usage of any particular host organism in which the polypeptides of the invention are to be expressed.
- Polvnucleotides of the invention may comprise DNA or RNA. They may be single- stranded or double-stranded. They may also be polvnucleotides which include within them synthetic or modified nucleotides. A number of different types of modification to oligonucleotides are known in the art. These include methylphosphonate and phosphorothioate backbones, addition of acridine or polylysine chains at the 3' and/or 5' ends of the molecule. For the purposes of the present invention, it is to be understood that the polynucleotides described herein may be modified by any method available in the art. Such modifications may be carried out in order to enhance the in vivo activity or life • span of polynucleotides of the invention. l
- variants in relation to the nucleotide sequence of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) nucleic acid from or to the sequence.
- variant, homologues or derivatives code for a polypeptide having biological activity, preferably having substantially the same activity as the GroEL apical domain (for example, amino acids 191 to 376 of the amino acid sequence shown as SEQ ID No. 1 ).
- Polynucleotides for use in the present invention will tvpically have at least 50 or 75% sequence homology. more preferably at least 85%. more preferably at least 90%) or 95% homology to the - - quence shown SEQ ID. No. 2 over a region of at least 20, preferably at least 25 or 30. for instance at least 40, 60 or 100 or more contiguous nucleotides.
- Preferred polynucleotides for use in the invention will comprise regions encoding polypeptide domains homologous to the apical GroEL domain, preferably at least 70, 80 or 90% and more preferably at least 95% homologous to said regions.
- Nucleotide homology comparisons may be conducted as described above for polypeptides.
- a preferred sequence comparison program is the GCG Winsconsin Bestfit program described above.
- the default scoring matrix has a match value of 10 for each identical nucleotide and - 9 for each mismatch.
- the default gap creation penalty is -50 and the default gap extension penalty is -3 for each nucleotide.
- nucleotide sequences for use in the present invention are typically capable of hybridising selectively to SEQ ID. No. 2 or any variant, fragment or derivative thereof, or to the complement of any of the above.
- Nucleotide sequences are preferably at least 15 nucleotides in length, more preferably at least 20, 30, 40 or 50 nucleotides in length.
- hybridization shall include "the process by which a strand of nucleic acid joins with a complementary strand through base pairing" as well as the process of amplification as carried out in polymerase chain reaction technologies.
- selective hybridizable means that the polynucleotide used as a probe is used under conditions where a target polynucleotide of the invention is found to hybridize to the probe at a level significantly above background. The background hybridization may occur because of other polynucleotides present, for example, in the cDNA or genomic DNA library being screening.
- background implies a level of signal generated by interaction between the probe and a non-specific DNA member of the library which is less than 10 fold, preferably less than 100 fold as intense as the specific interaction observed with the target DNA.
- the intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with J ⁇ P.
- Hybridization conditions are based on the melting temperature (Tm) of the nucleic acid binding complex, as taught in Berger and Kimmel (1987, Guide to Molecular Cloning Techniques. Methods in Enzymology. Vol 152, Academic Press. San Diego CA), and confer a defined "stringency” as explained below.
- Maximum stringency typically occurs at about Tm-5°C (5°C below the Tm of the probe); high stringency at about 5°C to 10°C below Tm: intermediate stringency at about 10°C to 20°C below Tm; and low stringency at about 20°C to 25°C below Tm.
- a maximum stringency hyb ⁇ ' dization can be used to identify or detect identical polynucleotide sequences while an intermediate (or low) stringency hybridization can be used to identify or detect similar or related polynucleotide sequences.
- both strands of the duplex are encompassed by the present invention.
- the polynucleotide is single-stranded, it is to be understood that the complementary sequence of that polynucleotide is also included within the scope of the present invention.
- Polynucleotides of the invention or for use in the present invention which are not 100% homologous to SEQ ID. No. 2 can be obtained in a number of ways.
- other viral/bacterial, or eukaryotic homologues may be obtained and such homologues and fragments thereof in general will be capable of selectively hybridising to the sequences shown in the sequence listing herein.
- sequences may be obtained by probing cDNA libraries made from or genomic DNA libraries from other species, and probing such libraries with probes comprising all or part of SEQ I.D. No 2 under conditions of medium to high stringency.
- Variants and strain/species homologues may also be obtained using degenerate PCR which will use primers designed to target sequences within the variants and homologues encoding conserved amino acid sequences within the sequences of the present invention.
- conserved sequences can be predicted, for example, by aligning the amino acid sequences from several variants/homologues. Sequence alignments can be performed using computer software known in the art. For example the GCG Wisconsin PileUp program is widely used.
- the primers used in degenerate PCR will contain one or more degenerate positions and will be used at stringency conditions lower than those used for cloning sequences with single sequence primers against known sequences.
- polynucleotides may be obtained by site directed mutagenesis of characterised sequences, such as SEQ ID. No 2. This may be useful where for example silent codon changes are required to sequences to optimise codon preferences for a particular host cell in which the polynucleotide sequences are being expressed. Other sequence changes may be desired in order to introduce restriction enzyme recognition sites, or to alter the property or function of the polypeptides encoded by the polynucleotides.
- Polynucleotides of the invention or for use in the present invention may be used to produce a primer, e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors.
- a primer e.g. a PCR primer, a primer for an alternative amplification reaction, a probe e.g. labelled with a revealing label by conventional means using radioactive or non-radioactive labels, or the polynucleotides may be cloned into vectors.
- primers, probes and other fragments will be at least 15, preferably at least 20, for example at least 25, 30 or 40 nucleotides in length.
- Polynucleotides such as a DNA polynucleotides and probes may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time Techniques for accomplishing this using automated techniques are readily available in the art
- Longer polynucleotides will generally be produced using recombinant means, for example using a PCR (polymerase chain reaction) cloning techniques This will involve making a pair of primers (e g of about 15 to 30 nucleotides) flanking a region of the hpid targeting sequence which it is desired to clone, bnnging the pnmers into contact with mRNA or cDNA obtained from an animal or human cell, performing a polymerase chain reaction under conditions which bring about amplification of the desired region, isolating the amplified fragment (e g by purifying the reaction mixture on an agarose gel) and recovenng the amplified DNA
- the pnmers may be designed to contain suitable restnction enzyme recognition sites so that the amplified DNA can be cloned into a suitable cloning vector
- Polynucleotides or pnmers of the invention may carry a revealing label Suitable labels include radioisotopes such as J" P or 3 S, enzyme labels, or other protein labels such as biotin Such labels may be added to polynucleotides or primers of the invention and may be detected using by techniques known pet se
- Polvnucleotides ot the invention can be incorporated into a recombinant rephcable vector
- the vector may be used to replicate the nucleic acid in a compatible host cell
- the invention provides a method of making polynucleotides of the invention by introducing a polynucleotide of the invention into a rephcable vector, introducing the vector into a compatible host cell, and growing the host cell under conditions which bring about replication of the vector
- the vector may be recovered from the host cell Suitable host cells include bacteria such as E coli, yeast, mammalian cell lines and other eukaryotic cell lines, for example insect Sf9 cells Preferably.
- a polynucleotide of the invention in a vector is operably linked to a control sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector.
- operably linked means that the components described are in a relationship permitting them to function in their intended manner.
- a regulatory sequence "operably linked" to a coding sequence is ligated in such a way that expression of the coding sequence is achieved under condition compatible with the control sequences.
- control sequences may be modified, for example by the addition of further transcriptional regulatory elements to make the level of transcription directed by the control sequences more responsive to transcriptional modulators.
- Vectors of the invention may be transformed or transfected into a suitable host cell as described below to provide for expression of a protein of the invention. This process may comprise culturing a host cell transformed with an expression vector as described above under conditions to provide for expression by the vector of a coding sequence encoding the protein, and optionally recovering the expressed protein. Vectors will be chosen that are compatible with the host cell used.
- the vectors may be for example, plasmid or virus vectors provided with an origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter.
- the vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian vector. Vectors may be used, for example, to transfect or transform a host cell.
- Control sequences operably linked to sequences encoding the polypeptide of the invention include promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell for which the expression vector is designed to be used in.
- the term promoter is well-known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal promoters to promoters including upstream elements and enhancers.
- the promoter is may typically be selected from promoters which are functional in prokaryotic cells or eukaryotic cells depending on the host cells in which it is desired to express the polypeptides of the invention.
- the promoter may be derived from promoter sequences of bacterial, viral or eukaryotic genes.
- it may be a promoter derived from the genome of a cell in which expression is to occur.
- eukaryotic promoters they may be promoters that function in a ubiquitous manner (such as promoters of ⁇ -actin, ⁇ -actin. tubulin) or. alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase). They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors.
- Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR) promoter, the rous sarcoma virus (RSV) LTR promoter or the human cytomegalovirus (CMV) IE promoter.
- MMLV LTR Moloney murine leukaemia virus long terminal repeat
- RSV rous sarcoma virus
- CMV human cytomegalovirus
- the promoters may also be advantageous for the promoters to be inducible so that the levels of expression of the polynucleotide of the invention can be regulated during the life-time of the cell. Inducible means that the levels of expression obtained using the promoter can be regulated.
- any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences.
- Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.
- Vectors and polynucleotides of the invention may be introduced into host cells for the purpose of replicating the vectors/polynucleotides and/or expressing the polypeptides of the invention encoded by the polynucleotides of the invention.
- Suitable host cells include prokaryotes such as eubacteria, for example E. coli and B. subtilis and eukaryotes such as yeast, insect or mammalian cells.
- Vectors/polynucleotides of the invention may be introduced into suitable host cells using a ⁇ anety of techniques known in the art, such as transfection, transformation and electroporation W r here vectors/polynucleotides of the invention are to be administered to animals, eral techniques are known in the art, for example infection with recombinant ⁇ iral vectors such as retroviruses. herpes simplex viruses and adenoviruses, direct injection of nucleic acids and biohstic transformation
- Host cells comprising polvnucleotides of the invention may be used to express polypeptides of the invention
- Host cells may be cultured under suitable conditions which allow expression of the proteins of the invention
- Expression of the polypeptides of the invention may be constitutive such that they are continually produced, or inducible, lequi ⁇ ng a stimulus to initiate expression
- protein production can be initiated when required by, for example, addition of an inducer substance to the culture medium, for example dexamethasone or IPTG.
- Polypeptides of the invention can be extracted from host cells by a variety of techniques known in the art. including enzymatic, chemical and/or osmotic lysis and physical disruption
- polypeptides may optionally be performed using well known techniques such as affinity chromatography, including lmmunoaffimty chromatography ion-exchange chromatography and the like
- affinity chromatography including lmmunoaffimty chromatography ion-exchange chromatography and the like
- a particularly preferred technique is to express the polypeptide of the invention as a fusion protein with polyhistidine tag (for example 6xH ⁇ s) and purify cell extracts using Ni-NTA agarose (Qiagen)
- polyhistidine tag for example 6xH ⁇ s
- Ni-NTA agarose Qiagen
- Polypeptides of the invention may also be produced recombinantly in an in vitro cell-free system, such as the TnTTM (Pro mega) rabbit reticulocyte system F. Antibodies.
- the invention also provides monoclonal or polyclonal antibodies to polypeptides of the invention or fragments thereof.
- the present invention further provides a process for the production of monoclonal or polyclonal antibodies to polypeptides of the invention.
- polyclonal antibodies are desired, a selected mammal (e.g.. mouse, rabbit, goat, horse, etc.) is immunised with an immunogenic polypeptide bearing GroEL epitope(s). Serum from the immunised animal is collected and treated according to known procedures. If serum containing polyclonal antibodies to an orbit epitope contains antibodies to other antigens, the polyclonal antibodies can be purified by immunoaffinity chromatography. Techniques for producing and processing polyclonal antisera are known in the art. In order that such antibodies may be made, the invention also provides polypeptides of the invention or fragments thereof haptemsed to another polypeptide for use as immunogens in animals or humans.
- Monoclonal antibodies directed against epitopes in the polypeptides of the invention can also be readily produced by one skilled in the art.
- the general methodology for making monoclonal antibodies by hybridomas is well known.
- Immortal antibody-producing cell lines can be created by cell fusion, and also by other techniques such as direct transformation of B lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus.
- Panels of monoclonal antibodies produced against orbit epitopes can be screened for various properties: i.e., for isotype and epitope affinity.
- An alternative technique involves screening phage display libraries where, for example the phage express scFv fragments on the surface of their coat with a large variety of complementarity determining regions (CDRs). This technique is well known in the art.
- Antibodies both monoclonal and polyclonal, which are directed against orbit epitopes are particularly useful in diagnosis, and those which are neutralising are useful in passive immunotherapy.
- Monoclonal antibodies in particular, may be used to raise anti-idiotype antibodies.
- Anti-idiotype antibodies are immunoglobulins which carry an "internal image" of the antigen of the agent against which protection is desired.
- anti-idiotype antibodies are known in the art. These anti-idiotype antibodies may also be useful in therapy.
- the term "antibody”, unless specified to the contrary, includes fragments of whole antibodies which retain their binding activity for a target antigen. Such fragments include Fv, F(ab') and F(ab') 2 fragments, as well as single chain antibodies (scFv). Furthermore, the antibodies and fragments thereof may be humanised antibodies, for example as described in EP-A-239400.
- Polypeptide chaperones of the invention may be used for altering the structure of a molecule, preferably a protein.
- Structural alterations include folding, unfolding and refolding. The effect of the alterations is preferably to improve the yield, specific activity and/or quality of the molecule. This may typically be achieved by resolubilising. reconditioning and/or reactivating incorrectly folded molecules post-synthesis and/or by acting on said molecules during their synthesis so as to ensure that the molecules adopt the correct conformation ab initio.
- in vitro procedures may include processing polypeptides that have been solubilised from cell extracts (such as inclusion bodies) using strong denaturants such as urea or guanidium chloride.
- refold reactivate
- recondition reactivating an inactive protein, perhaps denatured using urea, may have an unfolded structure. This inactive protein may then be refolded with a polypeptide of the invention thereby reactivating it. In some circumstances there may be an increase in the specific activity of the refolded/reactivated protein compared to the protein prior to inactivation/denaturation: this is termed "reconditioning".
- the molecule is typically an unfolded or misfolded polypeptide which is in need of folding. Alternatively, however, it may be a folded polypeptide which is to be maintained in a folded state.
- the polypeptide contains at least one disulphide linkage (or two cysteine residues capable of forming such as linkage under suitable conditions).
- the invention envisages at least two situations.
- a first situation is one in which the polypeptide to be folded is in an unfolded or misfolded state, or both. In this case, its correct folding is promoted by the method of the invention.
- a second situation is one in which the polypeptide is substantially already in its correctly folded state, that is all or most of it is folded correctly or nearly correctly.
- the method of the invention serves to maintain the folded state of the polypeptide by affecting the folded/unfolded equilibrium so as to favour the folded state. This prevents loss of activity of an already substantially correctly folded polypeptide.
- a polypeptide may be unfolded when at least part on? has not yet acquired its correct or desired secondary or tertiary structure.
- a polypeptide is misfolded when it has acquired an at least partially incorrect or undesired secondary or tertiary structure.
- In vitro procedures will generally comprise contacting the molecule and the chaperone polypeptide of the present invention.
- the molecule may have been intentionally inactivated or denatured using, for example urea, prior to contacting with the chaperone polypeptide.
- the contact occurs with the molecular chaperone immobilised on a solid support.
- solid supports include beads, "chips", resins, matrices, gels, and the material forming the walls of a vessel. Matrices, and in particular gels, such as agarose gels, may conveniently be packed into columns.
- a particular advantage of solid phase immobilisation is that the reagents may be removed from contact with the polypeptide(s) with facility.
- Immobilisation of the chaperone polypeptides of the present invention may be by covalent bonding or other means.
- an immobilisation method is used which comprises a reversible thiol blocking step. This is important where the peptide contains a disulphide bond.
- the disulphides are reduced using a reducing agent such as DTT (dithiothreitol), under for example an inert gas. such as argon, to prevent reoxidation.
- the polypeptide is cyanylated, for example using NCTB (2-nitro, 5-thiocyanobenzoic acid) preferably in stoichiometric amounts, and subjected to controlled hydrolysis at high (non-acidic) pH. for example using NaHC0 3 .
- NCTB 2-nitro, 5-thiocyanobenzoic acid
- controlled hydrolysis at high (non-acidic) pH. for example using NaHC0 3 .
- the thiols are thus reversibly protected.
- the chaperone polypeptide is then brought into contact with the solid phase component, for example at between 2.0 and 20.0 mg polypeptide/ml of solid component, preferably between 5.0 and 10.0 and most preferably around about 6.5 mg.
- the coupling is again carried out at a high (non-acidic) pH, for example using an NaHCOs coupling buffer.
- the remaining active groups may be blocked, such as with ethanolamine. and the uncoupled polypeptide removed by washing.
- Thiol groups may finally be regenerated on the coupled polypeptide by removal of the cyano groups, for example by treatment with DTE or DTT.
- Treatment of the molecule which is to reconditioned, refolding, resolubilised and/or reactivated may be performed simply be incubating the molecule in aqueous solution with the chaperone polypeptide.
- the polypeptide may be immobilised to a solid phase as described above, preferably a chromatographic matrix, and the contacting of the molecule and chaperone polypeptide is carried out by applying the molecule to the top of a bed of the matrix packed in a column and then eluting the molecule through the column using standard techniques.
- incubations take place under reducing conditions, which may, for example, be achieved using a combination of oxidised glutathione (GSSG) and glutathione (GSH) which act as a redox buffer system and prevent formation of disulphide bonds present in the oxidised state.
- GSSG oxidised glutathione
- GSH glutathione
- the stoichiometry between the chaperone polypeptide of the invention and the molecule being altered is about 1 : 1. preferably 1 : 1.
- polypeptides of the invention may also be used in vivo.
- a known problem associated with high level expression of polypeptides is that the large amounts of synthesised protein present in the cell cannot be processed properly by the cell's own machinery. In, for example, bacteria, this leads to deposits of insoluble protein in inclusion bodies that may only be solubilised in powerful denaturants such as urea and guanidium chloride.
- Co-expression of chaperone polypeptides of the invention may be used to assist the host cell in processing polypeptides expressed at high levels thus increasing the amount of properly folded soluble active protein which may be extracted using relatively mild techniques.
- the invention also provides for the use of a polypeptide of the invention in the production of a protein or polypeptide by recombinant means, wherein the said polypeptide is co-expressed with the protein or polypeptide thereby to improve the yield, activity and/or quality of the protein or polypeptide.
- Chaperone polypeptides of the invention may be used in combination with another polypeptide that alters the structure of molecules, such as other components of cellular protein refolding machinery, for example foldases.
- the foldase is selected from thiol/disulphide oxidoreductases and peptidyl prolyl isomerases. Specific examples include cyclophilin and thiol/disulphide oxidoreductases selected from E. coli DsbA and mammalian protein disulphide isomerase.
- Other polypeptides include members of the hsp70 family of chaperones, such as Gro ⁇ S. Further details of refolding methods using molecular chaperones together with foldases are described in WO99/05163, the contents of which are incorporated herein by reference. H. Therapeutic uses
- Some human diseases such as Alzheimer ' s disease and prion diseases including Creutzfeld-Jacob's disease are known to be associated with aberrant protein/polypeptide structure.
- Administration of polypeptides of the invention, either directly or via nucleic acid constructs, to affected cells may be used to the treatment of said diseases.
- the aberrant nature of the protein/polypeptide may be due to misfolding or unfolding which in turn may be due to an anomalous e.g. mutated amino acid sequence.
- the protein/polypeptide may be destabilised or deposited as plaques, for example as in Alzheimer's disease.
- the disease might be caused by a prion.
- a polypeptide-based medicament of tu-- invention would act to renature or resolubilise aberrant, defective or deposited proteins.
- a polypeptide of the invention for the manufacture of a medicament for the treatment of disease associated with aberrant protein/polypeptide structure.
- a nucleic acid molecule in accordance with other aspects of the invention for use in the treatment of disease. Consequently, there is provided the use of a nucleic acid molecule of the invention for the manufacture of a medicament for the treatment of disease associated with protein/polypeptide structure.
- Genetic therapy in vivo is therefore provided for by way of introduction and expression of DNA encoding the chaperone polypeptide in cells/tissues of an individual to provide chaperonin activity in those cells/tissues.
- An antibody reactive against a polypeptide of the invention may also be used for the treatment of disease, such as disease associated with protein/polypeptide structure.
- Polypeptides of the invention may also be used in a method of treating disease which comprises administering an effective amount of an inhibitor of the chaperone activity of a polypeptide of the invention.
- said inhibitor is an antibody. L Administration
- Polypeptides and/or antibodies of the invention may preferably be combined with various components to produce compositions of the invention.
- the compositions are combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition (which may be for human or animal use).
- Suitable carriers and diluents include isotonic saline solutions, for example phosphate-buffered saline.
- the composition of the invention may be administered by direct injection.
- the composition may be formulated for parenteral, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.
- each protein may be administered at a dose of from 0.01 to 30 mg/kg body weight, preferably from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.
- Polynucleotides/vectors encoding polypeptide components for use in therapy may be administered directly as a naked nucleic acid construct. They may further comprise flanking sequences homologous to the host cell genome. When the polynucleotides/vectors are administered as a naked nucleic acid, the amount of nucleic acid administered may typically be in the range of from 1 ⁇ g to 10 mg, preferably from 100 ⁇ g to 1 mg. It is particularly preferred to use polynucleotides/vectors that target specifically tumour cells, for example by virtue of suitable regulatory constructs or by the use of targeted viral vectors.
- Uptake of naked nucleic acid constructs by mammalian cells is enhanced by several known transfection techniques for example those including the use of transfection agents.
- transfection agents include catio ic agents (for example calcium phosphate and DEAE-dextran) and lipofectants (for example lipofectamTM and transfectamTM).
- catio ic agents for example calcium phosphate and DEAE-dextran
- lipofectants for example lipofectamTM and transfectamTM.
- nucleic acid constructs are mixed with the transfection agent to produce a composition.
- the polynucleotide or vector according to the invention is combined with a pharmaceutically acceptable carrier or diluent to produce a pharmaceutical composition.
- Suitable carriers and diluents include isotonic saline solutions, for example phosphate- buffered saline.
- the composition may be formulated for parenteral. intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.
- FIG. 1 Three-dimensional structure of minichaperone GroEL(191-345) (PDB ID: IKID; Buckle et al, 1997). Residues included in the multiple mutants Ml and M2 (A212, A223, M233. 1305, E308 and N326) are indicated. Drawn with MOLSCRIPT (Kraulis, 1991) and RASTER3D (Merritt & Murphy, 1994).
- Figure 3 In vitro refolding of human CyPA in the presence of various chaperones. They are: no chaperone (Spont.), 0.94 ⁇ M GroEL, 0.94 ⁇ M GroEL(193-345), 0.94 ⁇ M Ml, and 0.94 ⁇ M M2. The final concentration of CyPA is 0.94 ⁇ M. One hundred percent activity was obtained with native CyPA. Standard error bars are shown.
- the chemical denaturation was performed using urea as denaturant in 50 mM Tris ⁇ Cl, 150 mM NaCI, pH 8.2 at 25 °C. monitored at 218nm using a Jasco J-720 spectropolarimeter with cuvettes of pathlength of 0.1 cm, essentially as described previously (Golbik et al. 1998).
- the plots of CD signals at 218 nm versus urea concentrations were fitted to a two- state equation (Clarke & Fersht. 1993) using the program KaleidaGraphTM:
- F is the recorded CD signal
- ⁇ N and a D are the intercepts
- b N and b O are the slopes of the pre-transition and post-transition regions where proteins are in native (N) and denatured (D) states
- [urea] 50% is the concentration of urea at which 50%o of the proteins is denatured
- mo- N is the slope of the transition region which reflects the sensitivity to chemical denaturant (urea)
- R is the gas constant
- -T is the absolute temperature.
- Human CyPA was denatured by incubating the protein (94 ⁇ M) in 100 mM potassium phosphate, 10 mM DTT, pH 7 0 and 8 M urea at 30 °C for at least 16 h Refolding of CyPA was initiated by diluting the urea-denatured protein 100-fold to a final concentration of 0 94 ⁇ M in 100 mM potassium phosphate.
- T m values of these five mutants were analyzed by differential scanning calorimetry (DSC), the increases range from 1.55 to 6.78 °C (Table 4).
- A212 is located in a loop between ⁇ -strands S6 and S7 and is almost completely buried.
- the side chain of A212 is about 4 A away from the side chains of K207 and V213, and is surrounded by potential hydrogen-bonding partners from residues T210, G21 1 , V213, 1325 and water molecules.
- the mutation A212E stabilizes the protein by 1.38 kcal mob 1 and 5.63 ° C. This could be the result of the enhanced hydrophobic packing due to the introduction of one methylene group, and hydrogen bonding with the introduced carboxyl group.
- A223 is the C-terminal residue of ⁇ -strand S8 and is located in the hydrophobic core. It occurs with a frequency of 7% in the Cpn60 family. A223 is surrounded by the methyl(ene) groups of 1227. A251 and 1301 , and hydrogen-bonding groups of L222, D224. K225, A250 and 1301. all within a radius of 4.5 A.
- the mutation A223T stabilizes the protein by 1.55 kcal mob' and 5.60 °C. As for the mutation A212E. the source of the stabilization is likely to be the increased hydrophobic packing and hydrogen-bonding interactions.
- residue A223 is nearly completely buried in the hydrophobic core, the more hydrophobic substitution A223V is 0.52 kcal mob 1 and 4.05 °C less stable than its isosteric substitution A223T.
- the most stabilizing mutation is M233L, a similar-size replacement on the buried face of ⁇ - helix H8 that participates in the hydrophobic core.
- the side chain of M233 displays two conformations, indicating intrinsic local disorder in the wild-type protein that may stabilize the protein entropically.
- residues within 4.5 A namely L221, 1227, 1230, V236, L237, L247, 1249 and L262, form a small hydrophobic cluster.
- 1230 and L237 have been postulated to interact with substrates (Fenton et al, 1994; Buckle et al , 1997).
- N326 is the C-terminal residue of ⁇ -strand Sl l, with 53% of its side chain accessible to solvent. Its close neighbours within 4.5 A are mainly oxygen and nitrogen atoms from surrounding residues 1325. K327, D328 and T329. The mutation N326T stabilizes the protein by 1.35 kcal mob 1 and 6.78 °C. where hydrogen-bonding interactions may contribute to the enhanced stability.
- T294 is located in ⁇ -helix H10 close to its C-terminus. and has a solvent accessibility of 17%).
- the mutation T294R stabilizes the protein by 0.37 kcal mob 1 .
- Stabilization may be the result of the favorable electrostatic interaction between the helical dipole and the introduced R294.
- 1305 and E308 are located in the solvent-exposed segment of a mobile loop between H10 and SI 1.
- the region between residues 301 and 308 is the least resolved in the crystal structures of intact GroEL (Braig et al. 1995), which suggests an inherent flexibility of this region.
- the mutations I305L, E308K and E308S stabilize the protein by 0.69, 0.34 and 0.47 kcal mob 1 respectively.
- I305L and E308K are included in two multiple mutants described below.
- Other mutations K207N. S217D, M267L and V271L stabilize the protein by 0.27, 0.15, 0.13 and 0.15 kcal mo
- A223T, A223V, M233L and V236L are clustered in the hydrophobic core that buttresses the substrate-binding site of GroEL.
- A212E/A223V/M233L/I305L/E308K/N326T were constructed, each encompassing six stabilizing mutations (Figure 1).
- the only difference between Ml and M2 is the residue at position 223; T223 in Ml , whereas V223 in M2.
- the values of [urea] 50% are 6.37 and 5.98
- the T m values measured by DSC are 85.66 °C for Ml and 81.26 °C for M2, 18.58 °C and 14.18 °C higher than that of wild type respectively
- CyPA is a peptidyl-prolyl cis-trans isomerase with a molecular mass of 18 kDa.
- the refolding of denatured CyPA requires the assistance of GroEL (Zahn et al, 1994) or minichaperones (Zahn et al, 1996) in order to achieve a high recovery of activity.
- the highly stable minichaperone variants Ml and M2 demonstrate high activity in assisting the refolding of CyPA. at the same level as full-length GroEL and wild-type GroEL( 193-345) ( Figure 3). Spontaneous refolding of CyPA has been reported to be about 30%> in the absence of chaperones.
- N > is the average value 2.23 ⁇ 0.05 for GroEL( 193-335) and its mutants. Positive values of ⁇ G"i° decreased stability whereas negative values indicate increased stability.
- the numbers refer to residue positions, while the letters represent amino acid residues. For example, position 207 is mutated to N.
- N206T 2.28-1-0.05 2.79-L0.01 6.4-1-0.1 0.2 ⁇ 0.2 0.71 ⁇ 0.02
- T m is the midpoint of thermal denaturation.
- Ml includes six mutations: A212E, A223T, M233L, I305L, E308K and N326T, while GroEL( 193-345)
- M2 includes six mutations: A212E, A223V, M233L, I305L, E308K and N326T.
- C ⁇ G ⁇ --" U is the sum °f the effects on protein stability ( ⁇ GJ"" 1 ** ) of all constituent single mutations.
- AKAGKPLL I EDVEGEALA TLWNTMRGI VKVAAVKAPG FGDRRKAMLQ DIATLTGGTV
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00931425A EP1183364A1 (en) | 1999-05-27 | 2000-05-26 | Groel muteins with improved stability |
CA002375095A CA2375095A1 (en) | 1999-05-27 | 2000-05-26 | Groel muteins with improved stability |
AU49379/00A AU4937900A (en) | 1999-05-27 | 2000-05-26 | Groel muteins with improved stability |
JP2001500775A JP2003501037A (en) | 1999-05-27 | 2000-05-26 | GroEL mutant protein with improved stability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9912445.5 | 1999-05-27 | ||
GBGB9912445.5A GB9912445D0 (en) | 1999-05-27 | 1999-05-27 | Molecular chaperones |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000073463A1 true WO2000073463A1 (en) | 2000-12-07 |
Family
ID=10854343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/002019 WO2000073463A1 (en) | 1999-05-27 | 2000-05-26 | Groel muteins with improved stability |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1183364A1 (en) |
JP (1) | JP2003501037A (en) |
AU (1) | AU4937900A (en) |
CA (1) | CA2375095A1 (en) |
GB (1) | GB9912445D0 (en) |
WO (1) | WO2000073463A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116486903A (en) * | 2023-04-17 | 2023-07-25 | 深圳新锐基因科技有限公司 | Method and device for improving protein stability based on combination of homologous protein sequence evolution direction and free energy change |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998013496A1 (en) * | 1996-09-26 | 1998-04-02 | Medical Research Council | Chaperone fragments |
WO1999002989A1 (en) * | 1997-07-10 | 1999-01-21 | Medical Research Council | Chaperone fragments |
-
1999
- 1999-05-27 GB GBGB9912445.5A patent/GB9912445D0/en not_active Ceased
-
2000
- 2000-05-26 WO PCT/GB2000/002019 patent/WO2000073463A1/en not_active Application Discontinuation
- 2000-05-26 CA CA002375095A patent/CA2375095A1/en not_active Abandoned
- 2000-05-26 AU AU49379/00A patent/AU4937900A/en not_active Abandoned
- 2000-05-26 EP EP00931425A patent/EP1183364A1/en not_active Withdrawn
- 2000-05-26 JP JP2001500775A patent/JP2003501037A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998013496A1 (en) * | 1996-09-26 | 1998-04-02 | Medical Research Council | Chaperone fragments |
WO1999002989A1 (en) * | 1997-07-10 | 1999-01-21 | Medical Research Council | Chaperone fragments |
Non-Patent Citations (10)
Title |
---|
ALTAMIRANO, M.M. ET AL.: "Refolding chromatography with immobilized mini-chaperones.", PROC.NAT'L.ACAD.SCI.USA, vol. 94, April 1997 (1997-04-01), pages 3576 - 8, XP002147144 * |
CHATELLIER JEAN ET AL: "In vivo activities of GroEL minichaperones", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES,NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC,US, vol. 95, no. 17, 18 August 1998 (1998-08-18), pages 9861 - 9866, XP002145051, ISSN: 0027-8424 * |
FENTON, W.A. ET AL.: "Residues in chaperonin GroEL required for polypeptide binding and release.", NATURE, vol. 371, 13 October 1994 (1994-10-13), pages 614 - 9, XP002147146 * |
FERNANDEZ R C ET AL: "Cloning and sequencing of the Bordetella pertussis cpn10cpn60 (groESL) homolog", GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 158, no. 1, 1995, pages 151 - 152, XP004206638, ISSN: 0378-1119 * |
GOLBIK RALPH ET AL: "Thermodynamic stability and folding of GroEL minichaperones.", JOURNAL OF MOLECULAR BIOLOGY, vol. 276, no. 2, 20 February 1998 (1998-02-20), pages 505 - 515, XP000939379, ISSN: 0022-2836 * |
LOVE B C ET AL: "Cloning and sequence of the groESL heat-shock operon of Pasteurella multocida", GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 166, no. 1, 1995, pages 179 - 180, XP004043133, ISSN: 0378-1119 * |
NIKOLOVA, P.V. ET AL.: "Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability.", PROC.NAT'L.ACAD.SCI.USA, vol. 95, December 1998 (1998-12-01), pages 14675 - 80, XP002147145 * |
SERRANO L ET AL: "STEP-WISE MUTATION OF BARNASE TO BINASE. A PROCEDURE FOR ENGINEERING INCREASED STABILITY OF PROTEINS AND AN EXPERIMENTAL ANALYSIS OF THE EVOLUTION OF PROTEIN STABILITY", JOURNAL OF MOLECULAR BIOLOGY,GB,LONDON, vol. 233, no. 2, 1993, pages 305 - 312, XP000644434, ISSN: 0022-2836 * |
WANG QINGHUA ET AL: "Stabilization of GroEL minichaperones by core and surface mutations.", JOURNAL OF MOLECULAR BIOLOGY, vol. 298, no. 5, 2000, pages 917 - 926, XP000939375, ISSN: 0022-2836 * |
WANG, Q. ET AL.: "Design of highly stable functional GroEL minichaperones.", PROTEIN SCIENCE, vol. 8, no. 10, October 1999 (1999-10-01), pages 2186 - 93, XP000939387 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116486903A (en) * | 2023-04-17 | 2023-07-25 | 深圳新锐基因科技有限公司 | Method and device for improving protein stability based on combination of homologous protein sequence evolution direction and free energy change |
CN116486903B (en) * | 2023-04-17 | 2023-12-29 | 深圳新锐基因科技有限公司 | Method and device for improving protein stability based on combination of homologous protein sequence evolution direction and free energy change |
Also Published As
Publication number | Publication date |
---|---|
JP2003501037A (en) | 2003-01-14 |
GB9912445D0 (en) | 1999-07-28 |
CA2375095A1 (en) | 2000-12-07 |
AU4937900A (en) | 2000-12-18 |
EP1183364A1 (en) | 2002-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Davidson et al. | Mutation of a single MalK subunit severely impairs maltose transport activity in Escherichia coli | |
AU736670B2 (en) | Chaperone fragments | |
Kawazoe et al. | Crystal structure of human D‐amino acid oxidase: context‐dependent variability of the backbone conformation of the VAAGL hydrophobic stretch located at the si‐face of the flavin ring | |
Anderson et al. | Characterisation of the molybdenum‐responsive ModE regulatory protein and its binding to the promoter region of the modABCD (molybdenum transport) operon of Escherichia coli | |
Botos et al. | The catalytic domain of Escherichia coli Lon protease has a unique fold and a Ser-Lys dyad in the active site | |
Schmitt et al. | Crystal structure of the nucleotide-binding domain of the ABC-transporter haemolysin B: identification of a variable region within ABC helical domains | |
Gonzalez et al. | A novel snare N-terminal domain revealed by the crystal structure of Sec22b | |
Correale et al. | Molecular organization of the cullin E3 ligase adaptor KCTD11 | |
Greene et al. | Role of conserved residues in structure and stability: Tryptophans of human serum retinol‐binding protein, a model for the lipocalin superfamily | |
Chen et al. | Regulatory features of the trp operon and the crystal structure of the trp RNA-binding attenuation protein from Bacillus stearothermophilus | |
Grandori et al. | The DNA-binding domain of the hexameric arginine repressor | |
Wada et al. | Crystal structure of Escherichia coli SufA involved in biosynthesis of iron–sulfur clusters: implications for a functional dimer | |
WO2000015803A1 (en) | Immunoglobulin binding protein | |
Arnaud-Arnould et al. | Crystal structure of the TLDc domain of human NCOA7-AS | |
US6162627A (en) | Methods of identifying inhibitors of sensor histidine kinases through rational drug design | |
EP1183364A1 (en) | Groel muteins with improved stability | |
Liao et al. | Characterization, cloning, and expression of porcine αB crystallin | |
Kong et al. | Contribution of glycine 146 to a conserved folding module affecting stability and refolding of human glutathione transferase p1-1 | |
WO2010001967A1 (en) | Construction of expression system for rna polymerase derived from influenza virus, crystallization of the rna polymerase, and screening method for anti-influenza agent | |
D’Ambrosio et al. | A novel member of the protein disulfide oxidoreductase family from Aeropyrum pernix K1: structure, function and electrostatics | |
AU2004230803A2 (en) | Immunogen, composition for immunological use and process for producing antibody using the same | |
Park et al. | Effect of tandem rare codon substitution and vector-host combinations on the expression of the EBV gp110 C-terminal domain in Escherichia coli | |
US20050288489A1 (en) | Voltage-dependent calcium channel beta subunit functional core | |
US6893844B1 (en) | DNA encoding a new human hepatoma derived growth factor and producing method thereof | |
Yeh et al. | Structures of the dimerization domains of the Escherichia coli disulfide-bond isomerase enzymes DsbC and DsbG |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 49379/00 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2375095 Country of ref document: CA Ref country code: JP Ref document number: 2001 500775 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2375095 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000931425 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000931425 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000931425 Country of ref document: EP |